GLORIA PHARMA.(SZ:002437) Zhong Guo Jing Ji Wang·2025-12-22 02:17Core Viewpoint - Jilin Sihuan Pharmaceutical Co., Ltd. has issued a public apology regarding non-compliant trading behaviors associated with its product "Nerve Growth Factor Injection," which disrupted market order and violated business ethics [4][8]. Group 1: Company Actions - The company has taken immediate actions, including terminating cooperation with the involved distribution company [4]. - A comprehensive internal review of all product distributors and compliance assessments has been initiated to ensure adherence to industry standards [4]. - The company has strengthened its compliance system by revising and enhancing regulations, clarifying penalties for violations, and conducting specialized training for partners [4]. Group 2: Industry Context - The pharmaceutical sales sector has been plagued by issues such as "kickbacks" and inflated drug prices, leading to increased costs for medical supplies [8]. - The National Medical Insurance Administration has established a credit evaluation system for pharmaceutical pricing and procurement, which penalizes companies based on court rulings or administrative actions [8]. - As of the end of 2024, 735 companies have been rated as untrustworthy, affecting their eligibility for product listing and centralized procurement [8].